PCRX (STOCKS)
Pacira BioSciences, Inc. Common Stock
$23.180000
-0.520000 (-2.19%)
Prev close: $23.700000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Frank D. Lee
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $923.60M
- Employees
- 790
- P/E (TTM)
- 68.30
- P/B (TTM)
- 1.40
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.73 | $0.66 | +0.0697 | +10.56% |
|
Mar 2026 (Q1)
|
$0.60 | $0.57 | +0.0254 | +4.42% |
|
Dec 2025 (Q4)
|
$0.57 | $0.92 | -0.3525 | -38.21% |
|
Sep 2025 (Q3)
|
$0.70 | $0.66 | +0.0351 | +5.28% |
Financial Statements
| Revenues | $746.16M |
| Benefits Costs and Expenses | $728.52M |
| Cost Of Revenue | $155.15M |
| Costs And Expenses | $726.29M |
| Gross Profit | $591.01M |
| Nonoperating Income/Loss | -$2.22M |
| Operating Expenses | $571.14M |
| Selling, General, and Administrative Expenses | $379.16M |
| Research and Development | $121.73M |
| Other Operating Expenses | $70.25M |
| Operating Income/Loss | $19.87M |
| Income/Loss From Continuing Operations After Tax | $14.64M |
| Income/Loss From Continuing Operations Before Tax | $17.65M |
| Income Tax Expense/Benefit | $3.01M |
| Net Income/Loss | $14.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $14.64M |
| Net Income/Loss Available To Common Stockholders, Basic | $14.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.35 |
| Diluted Earnings Per Share | $0.35 |
| Basic Average Shares | 83,308,000 |
| Diluted Average Shares | 84,377,000 |
| Assets | $1.24B |
| Current Assets | $615.22M |
| Inventory | $134.58M |
| Other Current Assets | $480.64M |
| Noncurrent Assets | $628.76M |
| Fixed Assets | $130.28M |
| Intangible Assets | $285.48M |
| Other Non-current Assets | $213.00M |
| Liabilities | $572.00M |
| Current Liabilities | $122.01M |
| Accounts Payable | $17.51M |
| Wages | $26.99M |
| Other Current Liabilities | $77.52M |
| Noncurrent Liabilities | $449.99M |
| Long-term Debt | $363.12M |
| Other Non-current Liabilities | $86.87M |
| Equity | $671.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $671.98M |
| Liabilities And Equity | $1.24B |
| Net Cash Flow From Operating Activities | $187.66M |
| Net Cash Flow From Operating Activities, Continuing | $187.66M |
| Net Cash Flow From Investing Activities | $94.15M |
| Net Cash Flow From Investing Activities, Continuing | $94.15M |
| Net Cash Flow From Financing Activities | -$376.18M |
| Net Cash Flow From Financing Activities, Continuing | -$376.18M |
| Exchange Gains/Losses | -$243.00K |
| Net Cash Flow | -$94.61M |
| Net Cash Flow, Continuing | -$94.37M |
| Comprehensive Income/Loss | $13.82M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $13.82M |
| Other Comprehensive Income/Loss | $13.82M |
| Other Comprehensive Income/Loss Attributable To Parent | -$821.00K |